BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFast™ Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFast™ is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The Company is developing high-value biosimilars both internally and collaboratively.